Uncategorized Archives - Page 18 of 232

TuesdayOct 25, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline

Lexaria Bioscience is a global innovator in drug delivery platforms that has developed the patented DehydraTECH(TM) technology for improved delivery of bioactive compounds The company is currently evaluating DehydraTECH-processed CBD as a potential treatment for high blood pressure Long-term studies have shown that high blood pressure can increase the risk of developing dementia in later life Experts, however, believe that hypertension medication could slow the pace of the cognitive decline In addition to helping hypertension patients keep their condition under control, Lexaria’s DehydraTECH-CBD, which has so far been shown to be safe and well tolerated, could potentially help reduce the…

MondayOct 24, 2022 9:00 am

Advanced Container Technologies Inc. (ACTX) Leaders Talk Game-Changing Microfarm Growing Option on Episode of Leading Podcast

ACTX CEO Doug Heldoorn, Grow Pod inventor Shannon Illingworth discuss the innovative microfarm option on recent Gamechangers LIVE podcast Discussion focuses on history of company, significant health and safety benefits of Grow Pods Company is dedicated to developing, manufacturing and selling advanced cultivation equipment and packaging systems Advanced Container Technologies (OTC: ACTX) chair and CEO Doug Heldoorn was a featured guest on a recent episode of the Gamechangers LIVE podcast (https://cnw.fm/3xv5t). Heldoorn was joined by Shannon Illingworth, inventor of Grow Pods, the microfarm containers that ACTX distributes throughout the United States. During the podcast, the two men discussed the origins…

WednesdayOct 19, 2022 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Novel DehydraTECH(TM) Technology to Address Unmet Antihypertension Drug Market

Research has shown that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness The antihypertension drug market is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031 Lexaria’s patented DehydraTECH(TM) technology offers higher bioavailability of active pharmaceutical ingredients due to, in part, bypassing first-pass-liver processing, improving the speed of onset, and brain absorption The American Heart Association (“AMA”) refers to high blood…

WednesdayOct 19, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Building Portfolio of Brands that Resonates with End Consumers as It Targets Margins and Profitability

Flora Growth is a global cannabis company building a connected, design-led collective of plant-based wellness and lifestyle brands The company’s portfolio of brands is designed to deliver the most compelling customer experiences in the world Through its M&A strategy, Flora Growth has brought on board brands like JustCBD, Vessel Brands Inc., Masaya, No Cap Hemp Co., and Mambe Flora hopes to establish meaningful connections with consumers through these brands, which will enable it to increase its margins and profitability The cannabis industry has gone global, undergoing a sea change in commercialization, normalization, and liberalization. According to a report by New…

MondayOct 17, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments

Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs Lexaria has so far shown that its DehydraTECH-CBD is…

MondayOct 17, 2022 9:00 am

Changing Legal Landscape for Cannabis in Colombia and the U.S. Portends a New Era of Productivity for Flora Growth Corp. (NASDAQ: FLGC)

Colombia and the United States have both recently exhibited new openness to the possibility of decriminalizing adult recreational cannabis use through legislative change Cannabis supplier Flora Growth cultivates its product at a key Colombian farm and provides it to international markets, and may see additional opportunities arise as cannabis policies advance in the two countries Flora Growth recently announced completion of its first shipments of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States The company also recently reported a 604 percent YOY increase in revenues…

ThursdayOct 13, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension

Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participants Dominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026 In the United States, over 121.5 million adults are affected by high blood pressure – with statistics stacked against people of color, those with a family history of high…

TuesdayOct 11, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Offering Solutions to Growing Hypertension Problem Worldwide

Hypertension affects nearly half of all adults in the United States – 47% or 116 million people, some of which are medication-resistant A recent study from the University of Toledo College of Medicine and Life Sciences concluded gut bacteria might be the cause of medication-resistant hypertension – as demonstrated in rats used to conduct the study Lexaria’s patented DehydraTECH(TM) technology offers a viable solution for hypertension drug administration and has been received favorably by the FDA during a pre-Investigational New Drug meeting Hypertension, or high blood pressure, remains one of the world’s most deadly health problems, considered a silent killer…

MondayOct 10, 2022 11:15 am

Rosy Outlook for Global Cannabis Market Boosts Hopes for Flora Growth Corp. (NASDAQ: FLGC) as Supply Chain Expands

Cannabis grower and product maker Flora Growth is developing its own approach to riding troubling economic forces, boasting a 604 percent YOY increase in the H1 reporting period this year Market analysts predict the global cannabis market’s value will rise during the next five years at a CAGR of 24.3 percent to arrive at annual valuation of $82.3 billion Flora Growth is levying the potential of recent cooperative agreements to increase the reach of its product distribution pipeline, including new exports to Switzerland, the Czech Republic and the United States Europe is predicted to be the fastest-growing region for cannabis…

FridayOct 07, 2022 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD

Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertension A 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten years This decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugs At the same time, only 24% of adults with hypertension have the condition under control, a statistic attributable to the medications’ troublesome side effects Lexaria’s investigations of its DehydraTECH-CBD have so far presented favorable safety and tolerability data, meaning its drug candidate could offer reprieve to millions…

News and publishing service for CBD related companies

Contact us: 512.354.7000

Category: Uncategorized